Protalix BioTherapeutics’ Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology
Protalix BioTherapeutics announced this morning the publicationof its pivotal Phase 3 data for taliglucerase alfa for GaucherDisease in Blood, the Journal of the American Society ofHematology. The publication serves as important…
September 13th, 2011
Posted in
Drug